AU2015289758B2 - Methods for evaluating lung cancer status - Google Patents

Methods for evaluating lung cancer status Download PDF

Info

Publication number
AU2015289758B2
AU2015289758B2 AU2015289758A AU2015289758A AU2015289758B2 AU 2015289758 B2 AU2015289758 B2 AU 2015289758B2 AU 2015289758 A AU2015289758 A AU 2015289758A AU 2015289758 A AU2015289758 A AU 2015289758A AU 2015289758 B2 AU2015289758 B2 AU 2015289758B2
Authority
AU
Australia
Prior art keywords
lung cancer
genes
subject
patients
bronchoscopy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015289758A
Other languages
English (en)
Other versions
AU2015289758A1 (en
Inventor
Michael Elashoff
Duncan H. Whitney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veracyte Inc
Original Assignee
Veracyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veracyte Inc filed Critical Veracyte Inc
Publication of AU2015289758A1 publication Critical patent/AU2015289758A1/en
Assigned to VERACYTE, INC. reassignment VERACYTE, INC. Request for Assignment Assignors: ALLEGRO DIAGNOSTICS CORP.
Priority to AU2021218178A priority Critical patent/AU2021218178A1/en
Application granted granted Critical
Publication of AU2015289758B2 publication Critical patent/AU2015289758B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/30—Microarray design
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
AU2015289758A 2014-07-14 2015-07-14 Methods for evaluating lung cancer status Active AU2015289758B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021218178A AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462024456P 2014-07-14 2014-07-14
US62/024,456 2014-07-14
US201562160403P 2015-05-12 2015-05-12
US62/160,403 2015-05-12
PCT/US2015/040437 WO2016011068A1 (en) 2014-07-14 2015-07-14 Methods for evaluating lung cancer status

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218178A Division AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Publications (2)

Publication Number Publication Date
AU2015289758A1 AU2015289758A1 (en) 2017-02-02
AU2015289758B2 true AU2015289758B2 (en) 2021-09-09

Family

ID=55078998

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015289758A Active AU2015289758B2 (en) 2014-07-14 2015-07-14 Methods for evaluating lung cancer status
AU2021218178A Abandoned AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021218178A Abandoned AU2021218178A1 (en) 2014-07-14 2021-08-20 Methods for evaluating lung cancer status

Country Status (8)

Country Link
US (2) US20160130656A1 (enExample)
EP (2) EP3916110A1 (enExample)
JP (2) JP6775499B2 (enExample)
KR (1) KR102461014B1 (enExample)
CN (2) CN114807368A (enExample)
AU (2) AU2015289758B2 (enExample)
CA (1) CA2954169A1 (enExample)
WO (1) WO2016011068A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1874962A2 (en) 2005-04-14 2008-01-09 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
EP2605018A1 (en) 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
CN109715830A (zh) * 2016-06-21 2019-05-03 威斯塔解剖学和生物学研究所 用于使用基因表达谱诊断肺癌的组合物和方法
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
KR102421109B1 (ko) * 2016-09-14 2022-07-14 필립모리스 프로덕츠 에스.에이. 개인의 생물학적 상태를 예측하기 위한 시스템, 방법 및 유전자 시그니처
US11244764B2 (en) 2016-12-21 2022-02-08 Cerner Innovation, Inc. Monitoring predictive models
WO2018216009A1 (en) * 2017-05-22 2018-11-29 The National Institute For Biotechnology In The Negev Ltd. Ben-Gurion University Of The Negev Biomarkers for diagnosis of lung cancer
CN110958853B (zh) * 2017-06-02 2023-08-25 威拉赛特公司 用于鉴定或监测肺病的方法和系统
WO2019126343A1 (en) 2017-12-19 2019-06-27 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
CN112399819B (zh) 2018-07-02 2024-08-23 3M创新有限公司 用于监测时间相关过程的传感系统和方法
KR102274564B1 (ko) * 2018-07-03 2021-07-07 (주) 프로큐라티오 빅데이터분석기반 암진단장치
CN108998531B (zh) * 2018-08-31 2021-10-01 昆明医科大学第一附属医院 肺癌下调长链非编码rna标志物及其应用
CN109615075B (zh) * 2018-12-14 2022-08-19 大连海事大学 一种基于多层聚类模型的居民日常行为识别方法
US20210287795A1 (en) * 2020-03-12 2021-09-16 Optellum Limited Cad device and method for assisting an estimation of lung disease from medical images
CN114277138B (zh) * 2020-03-30 2022-06-24 中国医学科学院肿瘤医院 外泌体arpc5、mboat2等在肺癌诊断中的应用
CN114410794B (zh) * 2020-03-30 2023-06-23 中国医学科学院肿瘤医院 外泌体miR-106b-3P、ARPC5在肺癌诊断中的应用
CN111863130A (zh) * 2020-04-07 2020-10-30 至本医疗科技（上海）有限公司 肿瘤免疫治疗预后标志物的筛选方法及应用
CN112034185A (zh) * 2020-09-11 2020-12-04 上海市胸科医院 Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途
IL306044A (en) * 2021-03-29 2023-11-01 Veracyte Inc Methods and systems for identifying health disorders
US12094107B2 (en) * 2021-04-07 2024-09-17 Optellum Limited CAD device and method for analyzing medical images
CN113444796B (zh) * 2021-06-29 2023-02-07 浙江医院 与肺癌相关的生物标志物及其在诊断癌症中的应用
KR102417602B1 (ko) * 2021-11-30 2022-07-07 (주)플라스바이오 인공 지능 모델 기반 종양 관리 장치 및 방법
CN114854755B (zh) * 2022-05-30 2023-05-23 陕西师范大学 一种抑制vstm2l表达的慢病毒载体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000098A2 (en) * 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
WO2009006323A2 (en) * 2007-06-29 2009-01-08 Abbott Laboratories Methods and marker combinations for screening for predisposition to lung cancer
WO2013163568A2 (en) * 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234623A1 (en) 2002-05-16 2003-12-02 Euro-Celtique, S.A. Use of gastrin releasing peptide (grp) and its receptor in cancer screening
WO2005047451A2 (en) 2003-11-12 2005-05-26 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
EP1874962A2 (en) * 2005-04-14 2008-01-09 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
EP2605018A1 (en) 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2007142936A2 (en) * 2006-05-30 2007-12-13 Duke University Prediction of lung cancer tumor recurrence
KR101443214B1 (ko) * 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
WO2008140774A2 (en) * 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
WO2009121070A1 (en) 2008-03-28 2009-10-01 The Trustees Of Boston University Multifactorial methods for detecting lung disorders
GB0811413D0 (en) * 2008-06-20 2008-07-30 Kanton Basel Stadt Gene expression signatures for lung cancers
MX355020B (es) * 2010-07-09 2018-04-02 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
KR20130017525A (ko) 2011-08-11 2013-02-20 주식회사 젠닥스 대장암, 유방암, 신장암 또는 갑상선암의 조기 진단을 위한 바이오 마커 및 이의 용도
EA201490533A1 (ru) * 2011-08-29 2014-08-29 Кардиодиикс, Инк. Способы и композиции для определения статуса в отношении курения
US9753043B2 (en) * 2011-12-18 2017-09-05 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
US20140220006A1 (en) * 2013-02-01 2014-08-07 Meso Scale Technologies, Llc Lung cancer biomarkers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000098A2 (en) * 2003-06-10 2005-01-06 The Trustees Of Boston University Detection methods for disorders of the lung
WO2009006323A2 (en) * 2007-06-29 2009-01-08 Abbott Laboratories Methods and marker combinations for screening for predisposition to lung cancer
WO2013163568A2 (en) * 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. P. SHRIVER ET AL, , JOURNAL OF THE NATIONAL CANCER INSTITUTE, GB, (2000-01-05), vol. 92, no. 1, doi:10.1093/jnci/92.1.24, ISSN 0027-8874, pages 24 - 33 *

Also Published As

Publication number Publication date
CA2954169A1 (en) 2016-01-21
CN114807368A (zh) 2022-07-29
AU2015289758A1 (en) 2017-02-02
US20210040562A1 (en) 2021-02-11
JP6775499B2 (ja) 2020-10-28
US20160130656A1 (en) 2016-05-12
KR102461014B1 (ko) 2022-10-31
JP2020182489A (ja) 2020-11-12
EP3169814B1 (en) 2022-05-04
EP3169814A4 (en) 2018-03-07
CN106795565B (zh) 2022-05-10
EP3916110A1 (en) 2021-12-01
WO2016011068A1 (en) 2016-01-21
KR20170053617A (ko) 2017-05-16
JP2017527304A (ja) 2017-09-21
AU2021218178A1 (en) 2021-09-09
CN106795565A (zh) 2017-05-31
EP3169814A1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
AU2015289758B2 (en) Methods for evaluating lung cancer status
Jamshidi et al. Evaluation of cell-free DNA approaches for multi-cancer early detection
Whitney et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy
EP3103046B1 (en) Biomarker signature method, and apparatus and kits therefor
JP2025106239A (ja) 病原体検出のための配列決定データを使用するためのシステムおよび方法
JP5405110B2 (ja) 原発不明がんの原発巣を同定するための方法および材料
US12297505B2 (en) Algorithms for disease diagnostics
CN103502473B (zh) 胃肠胰神经内分泌肿瘤(gep-nen)的预测
US20150088430A1 (en) Methods for evaluating lung cancer status
CN118522390A (zh) 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
JP2020522690A (ja) 肺疾病の特定又はモニタリング方法及びシステム
CN108323184A (zh) 验证生物标志物测量
EP2751292A1 (en) Methods and compositions for detecting cancer based on mirna expression profiles
WO2013049152A2 (en) Methods for evaluating lung cancer status
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
AU2020398660A1 (en) Machine learning techniques for gene expression analysis
US20220148677A1 (en) Methods and systems for detecting genetic fusions to identify a lung disorder
US20240327927A1 (en) Active surveillance and risk stratification for prostate cancer
US20250305051A1 (en) Systems and methods of diagnosing idiopathic pulmonary fibrosis
CN119487214A (zh) 膀胱癌生物标志物和使用方法
Gómez-Martín et al. Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma
WO2022120076A1 (en) Clinical classifiers and genomic classifiers and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VERACYTE, INC.

Free format text: FORMER APPLICANT(S): ALLEGRO DIAGNOSTICS CORP.

FGA Letters patent sealed or granted (standard patent)